Literature DB >> 28195508

Incidence of interval cancers in faecal immunochemical test colorectal screening programmes in Italy.

Paolo Giorgi Rossi1,2, Elisa Carretta1,2, Lucia Mangone1,2, Susanna Baracco3, Diego Serraino4, Manuel Zorzi3.   

Abstract

Objective In Italy, colorectal screening programmes using the faecal immunochemical test from ages 50 to 69 every two years have been in place since 2005. We aimed to measure the incidence of interval cancers in the two years after a negative faecal immunochemical test, and compare this with the pre-screening incidence of colorectal cancer. Methods Using data on colorectal cancers diagnosed in Italy from 2000 to 2008 collected by cancer registries in areas with active screening programmes, we identified cases that occurred within 24 months of negative screening tests. We used the number of tests with a negative result as a denominator, grouped by age and sex. Proportional incidence was calculated for the first and second year after screening. Results Among 579,176 and 226,738 persons with negative test results followed up at 12 and 24 months, respectively, we identified 100 interval cancers in the first year and 70 in the second year. The proportional incidence was 13% (95% confidence interval 10-15) and 23% (95% confidence interval 18-25), respectively. The estimate for the two-year incidence is 18%, which was slightly higher in females (22%; 95% confidence interval 17-26), and for proximal colon (22%; 95% confidence interval 16-28). Conclusion The incidence of interval cancers in the two years after a negative faecal immunochemical test in routine population-based colorectal cancer screening was less than one-fifth of the expected incidence. This is direct evidence that the faecal immunochemical test-based screening programme protocol has high sensitivity for cancers that will become symptomatic.

Entities:  

Keywords:  Mass screening; colorectal cancer; faecal occult blood test; interval cancers; sensitivity

Mesh:

Year:  2017        PMID: 28195508     DOI: 10.1177/0969141316686391

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  5 in total

1.  The First Screening Program for Colorectal Cancer in the North of Iran.

Authors:  Hossein-Ali Nikbakht; Javad Shokri-Shirvani; Hassan Ashrafian-Amiri; Haleh Ghaem; Ali Jafarnia; Sedigheh Alijanpour; Seyed-Mostaffa Mirzad; Soheil Hassanipour
Journal:  J Gastrointest Cancer       Date:  2020-03

2.  A multiple-dimension model for microbiota of patients with colorectal cancer from normal participants and other intestinal disorders.

Authors:  Jian Shen; Gulei Jin; Zhengliang Zhang; Jun Zhang; Yan Sun; Xiaoxiao Xie; Tingting Ma; Yongze Zhu; Yaoqiang Du; Yaofang Niu; Xinwei Shi
Journal:  Appl Microbiol Biotechnol       Date:  2022-02-26       Impact factor: 4.813

3.  Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective.

Authors:  Thuy Ngan Tran; Marc Peeters; Sarah Hoeck; Guido Van Hal; Sharon Janssens; Harlinde De Schutter
Journal:  Br J Cancer       Date:  2022-01-12       Impact factor: 9.075

4.  Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.

Authors:  Hanna Ribbing Wilén; Deborah Saraste; Johannes Blom
Journal:  J Med Screen       Date:  2022-03-08       Impact factor: 1.687

Review 5.  Aspects of colorectal cancer screening, methods, age and gender.

Authors:  R Hultcrantz
Journal:  J Intern Med       Date:  2020-09-14       Impact factor: 8.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.